healthcare - Oak Leaf Manor

3 min read

Uncategorized

Transitions Healthcare: What Do They Do To Help The Community?

April 15, 2021 olm0847

The Transitions Healthcare company is a health care facility that aims to provide innovative...

Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond December 3, 2024

Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly owned assets, one of which could compete with a Merck drug approved earlier this year. The post Takeda Pays $200M for Keros Therapeutics […]

Boosting HIPAA Compliance in EHR Systems with Privacy-by-Design December 3, 2024

Incorporating PbD into the software development process of EHR systems presents a strategy to protect information starting from the initial stages of development and, throughout the entire lifecycle of the software. The post Boosting HIPAA Compliance in EHR Systems with Privacy-by-Design appeared first on MedCity News.

Set the Data Free: Break the Chains of Information Silos December 3, 2024

When you combine clean data with longitudinal patient records and transparent access — that’s when you start seeing real transformation in care delivery. The post Set the Data Free: Break the Chains of Information Silos appeared first on MedCity News.

3 Innovations Philips Is Showcasing at RSNA 2024 December 3, 2024

Philips is showcasing its partnerships and new products at RSNA 2024, including an expanded collaboration with AWS and a CT scanner that the company said uses up to 80% less radiation than traditional systems. The post 3 Innovations Philips Is Showcasing at RSNA 2024 appeared first on MedCity News.

Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug December 3, 2024

Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing. The post Novartis Tries Again in Huntington’s, Putting Up […]